Inventiva SA
NASDAQ:IVA
Inventiva SA
Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. The company is headquartered in Daix, Occitanie and currently employs 100 full-time employees. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. The company is headquartered in Daix, Occitanie and currently employs 100 full-time employees. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
Lanifibranor Progress: Phase III pivotal study for lanifibranor in NASH was initiated, and trial design for the LEGEND combination study with empagliflozin was announced and received FDA IND acceptance.
Regulatory Milestones: Lanifibranor received extended Fast Track designation from the FDA and confirmation that its toxicology package is adequate for NDA filing.
Cedirogant Momentum: AbbVie successfully advanced cedirogant into Phase IIb for psoriasis after promising Phase Ib results, triggering a EUR 4 million milestone payment.
Financial Position: Cash balance is approximately EUR 95.4 million (close to $100 million), with a runway through Q1 2023; an at-the-market (ATM) program raised about $32 million.
R&D Spending: R&D expenses roughly doubled in 2021, driven by Phase III activities.
Site Impact: Phase III recruitment in Ukraine and Russia was paused due to the crisis, but additional sites are being activated to mitigate delays.
Upcoming Data: Key clinical readouts expected in the second half of 2022 (lanifibranor diabetes study), early 2023 (cedirogant Phase IIb), and second half of 2024 (lanifibranor Phase III).
